File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Transgenic B7-H3 therapy in oral squamous cell cancer

TitleTransgenic B7-H3 therapy in oral squamous cell cancer
Authors
Issue Date2008
PublisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/jcms
Citation
The 19th Congress of the European Association for Cranio-Maxillofacial Surgery, Bologna, Italy, 9-12 September 2008. In Journal of Cranio-Maxillofacial Surgery, 2008, v. 36 suppl 1., p. S41-S42, abstract O-163 How to Cite?
AbstractOBJECTIVES: Tumors may present antigens to T-cells, however they lack the costimulatory signals which is necessary to initialize an effective immunologic response. The present study was purposed to develop a tumor cell-based cancer vaccine by genetically modifying oral squamous cell cancer cell line Tca8113 with human B7-H3 immunoglobulin, and evaluate its efficacy on enhancing the tumor specific immune response. METHODS: T lymphocytes were isolated from nine healthy volunteers. The human B7-H3 gene was extracted from the isolated T lymphocytes. Tumor cell vaccine TCV-hB7-H3 and the mock control were prepared by transfecting Tca8113 cells with B7-H3 or mock vector. The expression of B7-H3 in Tca8113, mock control cells and tumor cell vaccine TCV-hB7-H3 was assayed respectively by flow cytomentry, RT-PCR and Western blot. After being stimulated with TCV-hB7-H3 or mock control, the proliferation, IFN-g expression and cytotoxicity of the T cells were assessed. Results: The expression of B7-H3 was not detected in the tumor cell TCa8113 and mock control, but in the cell vaccine TCV-hB7-H3. Compared to the mock control, the cell vaccine TCV-hB7-H3 significantly enhanced the proliferation, IFN-g expression, and cytotoxicity of the T cells. CONCLUSIONS: The genetically modified OSCC cells encoding B7-H3 enhance the induction of tumor specific immune response.
Persistent Identifierhttp://hdl.handle.net/10722/61377
ISSN
2015 Impact Factor: 1.592
2015 SCImago Journal Rankings: 1.010

 

DC FieldValueLanguage
dc.contributor.authorYang, Hen_HK
dc.contributor.authorZwahlen, RAen_HK
dc.contributor.authorChu, Men_HK
dc.contributor.authorLuo, Jen_HK
dc.contributor.authorZuo, DHen_HK
dc.contributor.authorSun, STen_HK
dc.date.accessioned2010-07-13T03:38:18Z-
dc.date.available2010-07-13T03:38:18Z-
dc.date.issued2008en_HK
dc.identifier.citationThe 19th Congress of the European Association for Cranio-Maxillofacial Surgery, Bologna, Italy, 9-12 September 2008. In Journal of Cranio-Maxillofacial Surgery, 2008, v. 36 suppl 1., p. S41-S42, abstract O-163en_HK
dc.identifier.issn1010-5182en_HK
dc.identifier.urihttp://hdl.handle.net/10722/61377-
dc.description.abstractOBJECTIVES: Tumors may present antigens to T-cells, however they lack the costimulatory signals which is necessary to initialize an effective immunologic response. The present study was purposed to develop a tumor cell-based cancer vaccine by genetically modifying oral squamous cell cancer cell line Tca8113 with human B7-H3 immunoglobulin, and evaluate its efficacy on enhancing the tumor specific immune response. METHODS: T lymphocytes were isolated from nine healthy volunteers. The human B7-H3 gene was extracted from the isolated T lymphocytes. Tumor cell vaccine TCV-hB7-H3 and the mock control were prepared by transfecting Tca8113 cells with B7-H3 or mock vector. The expression of B7-H3 in Tca8113, mock control cells and tumor cell vaccine TCV-hB7-H3 was assayed respectively by flow cytomentry, RT-PCR and Western blot. After being stimulated with TCV-hB7-H3 or mock control, the proliferation, IFN-g expression and cytotoxicity of the T cells were assessed. Results: The expression of B7-H3 was not detected in the tumor cell TCa8113 and mock control, but in the cell vaccine TCV-hB7-H3. Compared to the mock control, the cell vaccine TCV-hB7-H3 significantly enhanced the proliferation, IFN-g expression, and cytotoxicity of the T cells. CONCLUSIONS: The genetically modified OSCC cells encoding B7-H3 enhance the induction of tumor specific immune response.-
dc.languageengen_HK
dc.publisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/jcmsen_HK
dc.relation.ispartofJournal of Cranio-Maxillofacial Surgery-
dc.titleTransgenic B7-H3 therapy in oral squamous cell canceren_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1010-5182&volume=36 &issue=Suppl 1&spage=S41&epage=&date=2008&atitle=Transgenic+B7-H3+therapy+in+oral+squamous+cell+cancer.++the+19th+congress+of+the+European+Association+for+Cranio-Maxillofacial+Surgery,+9-12+September+2008,+Bologna,+Italiaen_HK
dc.identifier.emailZwahlen, RA: zwahlen@hku.hken_HK
dc.identifier.authorityZwahlen, RA=rp00055en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S1010-5182(08)71287-3-
dc.identifier.hkuros159631en_HK
dc.identifier.hkuros166596-
dc.identifier.volume36-
dc.identifier.issuesuppl. 1-
dc.identifier.spageS41, abstract O-163-
dc.identifier.epageS42, abstract O-163-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats